Related Experiment Video
Updated: Jan 27, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Cancer-testis antigens: An update on their roles in cancer immunotherapy
Background:
Several recent studies have assessed suitability of tumor antigens for immunotherapy. Based on the restricted expression pattern in somatic tissues, cancer-testis antigens (CTAs) are possible candidates for cancer immunotherapy. These antigens are expressed in various tumors including gastrointestinal, breast, skin and hematologic malignancies.
Objectives:
To find clinical trials utilizing CTAs in cancer patients.
Methods:
We searched PubMed, google scholar and specific websites that registers clinical trials.
Results:
A number of clinical trials have been designed to evaluate safety and efficacy of CTA-based treatments. The results of some of them have been promising. In the current literature search, we summarized the clinical trials of CTA-based therapies in cancer patients.
Conclusions:
Based on the availability of different formulations of CTA-based vaccines, future researches should compare efficiency of these modalities.
Insights
Cancer-testis antigens (CTAs) show promise for immunotherapy due to their tumor-specific expression. Clinical trials are evaluating CTA-based treatments, with some showing encouraging results for various cancers.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Cancer-testis antigens (CTAs) are identified as potential targets for cancer immunotherapy.
- CTAs exhibit restricted expression in normal somatic tissues but are found in various malignancies, including breast, skin, gastrointestinal, and hematologic cancers.
Purpose of the Study:
- To identify and summarize ongoing and completed clinical trials investigating the use of CTAs in cancer patients.
- To assess the current landscape of CTA-based cancer therapies in clinical development.
Main Methods:
- A comprehensive literature search was conducted using databases such as PubMed and Google Scholar.
- Searches also included specialized websites that register clinical trials to ensure a broad overview.
Main Results:
- Multiple clinical trials have been initiated to assess the safety and efficacy of CTA-based immunotherapies.
- Preliminary results from some trials indicate promising outcomes in cancer treatment.
Conclusions:
- The development of various CTA-based vaccine formulations warrants further research.
- Future studies should focus on comparative analyses to determine the most effective CTA-based therapeutic modalities.
Related Concept Videos
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

